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We evaluated the efficacy of CK6, a KIT monoclonal antibody, in a panel of human gastrointestinal stromal tumor (GIST)
xenograftmodels. Nudemicewere bilaterally transplantedwith humanGIST xenografts (four patient derived and two cell
line derived), treated for 3 weeks, and grouped as follows: control (untreated); CK6 (40 mg/kg, 3× weekly); imatinib (50
mg/kg, twicedaily); sunitinib (40mg/kg, oncedaily); imatinib+CK6; sunitinib+CK6 (samedosesand schedules as in the
single-agent treatments). Tumor volumeassessment,Westernblot analysis, andhistopathologywereused for evaluation
of efficacy. Statistical analysiswasperformedusingMann-WhitneyU (MWU) andWilcoxonmatched-pairs tests. CK6as a
single agent only reduced tumor growth rate in the UZLX-GIST3 model (P= .053, MWU compared to control), while in
none of the other GIST models an effect on tumor growth rate was observed. CK6 did not result in significant anti-
proliferative or pro-apoptotic effects in any of theGISTmodels, andmoreover, CK6 did not induce a remarkable inhibition
of KIT activation. Furthermore, no synergistic effect of combiningCK6with tyrosine kinase inhibitors (TKIs)wasobserved.
Conversely, in certain GIST xenografts, anti-tumor effects seemed to be inferior under combination treatment compared
to single-agent TKI treatment. In the GIST xenografts tested, the anti-tumor efficacy of CK6 was limited. No synergy was
observed on combination of CK6with TKIs in these GISTmodels. Our findings highlight the importance of using relevant
in vivo human tumor xenograft models in the preclinical assessment of drug combination strategies.
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Gastrointestinal stromal tumors (GISTs) are the most common
mesenchymal tumors of the digestive system [1]. About 95% of
GISTs show expression of KIT protein by immunohistochemistry
(IHC) [2]. KIT is a member of the family of class III receptor tyrosine
kinases (RTKs) and is composed of an extracellular (EC) domain,
consisting of five Ig-like repeats, a juxtamembrane, and a cytoplasmic
kinase domain, containing an ATP-binding (TK1) and phospho-
transferase (TK2) domain split by a kinase insert. In approximately
85% of clinical GIST cases, somatic activating KIT mutations are
found, being the main molecular driver in the oncogenesis of the
disease [3,4]. These mutations induce constitutional activation of
KIT and its signaling mediators, resulting in a modulation of cell
proliferation and survival. Another subset of GIST patients harbors
Table 1. Description of Xenograft Models Used in the Study
Xenograft Model Origin KIT Mutational Status Expected In Vivo Imatinib Sensitivity [16,18,30]
UZLX-GIST1 Patient biopsy Exon 11: p.V560D, htz Yes
UZLX-GIST2 Patient biopsy Exon 9: p.A502_Y503dup, htz Dose-dependent
UZLX-GIST3 Patient biopsy Exon 11: p.W557_V559delinsF, htz Yes
UZLX-GIST4 Patient biopsy Exon 11: p.K558_G565delinsR, htz Yes
GIST48 Cell line Exon 11: pV560D, hom + exon 17: pD820A, htz Resistant
GIST882 Cell line Exon 13: p.K642E, hom Yes
htz, heterozygous; hom, homozygous.
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growth factor receptor α (PDGFRA), belonging to the same RTK
family as KIT [5]. The dependence of tumor cells on KIT/PDGFRA
activation profiles GIST as a target for selective tyrosine kinase
inhibitors (TKIs) such as imatinib. Response to imatinib has been
shown to strongly depend on the KIT/PDGFRA genotype [6,7].
However, some patients are intolerant to imatinib, and even more
importantly, the majority of treated patients will experience imatinib
resistance during the course of therapy [8,9]. After imatinib failure,
alternative TKIs can be considered for treatment of advanced GIST,
such as sunitinib and regorafenib. Nevertheless, these TKIs provide
only limited clinical benefit and time to progression seems to shorten
with every consecutive line of treatment [10,11]. TKI resistance is
mainly acquired through secondary missense KIT/PDGFRA muta-
tions that hamper the activity of the TKIs or less frequently through
genomic KIT amplification. Importantly, multiple synchronous
resistant mutations can be present in the same patient at different
metastatic sites and even within one metastatic lesion [9]. The
heterogeneous nature of TKI resistance in GIST emphasizes the need
to develop and test novel treatment approaches that could potentially
override or delay TKI resistance.
In the majority of cases, imatinib-resistant mutations modify either
the TK1 or the TK2 domain of the RTK.Mutations in TK1 can still be
responsive to alternative KIT inhibitors (e.g., sunitinib), whereas those
in the latter are believed to yield uniform resistance to currently available
compounds [12]. However, in TKI-resistant GISTs, tumor cells still
primarily rely on KIT activation as an oncogenic driver. Importantly,
the ligand-binding domain remains unaffected in these TKI-resistant
GISTs. Therefore, drugs targeting the EC region (ligand binding) of the
KIT receptor could represent an attractive therapeutic strategy to
overcome TKI resistance in GISTs. Recently, Edris et al. demonstrated
that SR1, an anti-KITmonoclonal antibody, is able to inhibit growth of
human GIST cell lines in vitro [13]. Furthermore, SR1 inhibited tumor
growth also in vivo in GIST882 and GIST430 xenograft models.
Another KIT antibody, CK6, has recently demonstrated KIT
antagonist activity and tumor growth neutralizing properties in
melanoma and small cell lung carcinoma [14]. In the present study,
we tested the efficacy of CK6 in six GIST human xenograft models
characterized by different sensitivity to standard TKI treatment.Materials and Methods
GIST Xenografts
For this study, GIST xenografts were established by bilaterally
subcutaneous transplantation of humanGIST tumor fragments in female
adult athymic nu/nu NMRI mice (Janvier Laboratories, Saint-Berthevin
Cedex, France) as described before [15–18]. UZLX-GIST1, UZLX-
GIST2, UZLX-GIST3, and UZLX-GIST4 models were establishedusing biopsies or resection specimen obtained from GIST patients,
treated in the Department of General Medical Oncology, University
Hospitals Leuven. TheGIST48 andGIST882models were derived from
tumors resulting from subcutaneous injection of cells (both cell lines were
a kind gift from Dr J. A. Fletcher, Boston). A detailed characterization of
the used GIST xenograft models can be found in Table 1. Collection of
GIST tissue for xenografting is approved by the Medical Ethics
Committee, University Hospitals Leuven. All animal experiments were
conducted in accordance with Belgian law and approved by the Ethics
Committee for Laboratory Animals, KU Leuven.
Drugs and Reagents
CK6 was provided by ImClone Systems (New York City, NY) in
phosphate-buffered saline. Imatinib mesylate and sunitinib malate
were purchased from Sequoia Research Products Ltd (Pangbourne,
United Kingdom) and were dissolved, respectively, in sterile water
and citric buffer (pH 3.5).
The following polyclonal or monoclonal antibodies were used for
Western blot analysis and IHC: pKITY719 (recognizing human
pKITY721 site), α-tubulin, and HRP-labeled anti-rabbit Signal Stain
Boost IHC detection reagent were from Cell Signaling Technologies
(Danvers,MA); pKITY703was fromLife Technologies; KIT (CD117),
anti-rabbit Envision+ System and 3′-diaminobenzidine tetrahydrochlo-
ride were from DAKO (Carpinteria, CA); β-actin and tubulin were from
Sigma-Aldrich (Saint Louis, MO); Ki67 was from Thermo Scientific
(Waltham,MA); cleaved PARP (Cl-PARP) was from Abcam (Cambridge,
United Kingdom), and Reveal Decloaker was from Biocare Medical
(Concord, CA). Western Lightning Plus-ECL enhanced chemilumines-
cence substrate reagents came from PerkinElmer (Waltham, MA).
Study Design
A total of 171mice (333 tumors) was engrafted bilaterally withUZLX-
GIST1 (n = 24), UZLX-GIST2 (n = 36), UZLX-GIST3 (n = 30),
UZLX-GIST4 (n = 29), GIST48 (n = 29), or GIST882 (n = 23) tumors.
Animals were assigned to six different groups and dosed for 3 weeks as
follows: control group (untreated), CK6 group [40 mg/kg, 3× weekly;
intraperitoneal (i.p.) administration], imatinib group (50 mg/kg, twice
daily; orally by gavage), imatinib + CK6 group (dosed and scheduled as
above), sunitinib group (40 mg/kg, once daily; orally by gavage), and
sunitinib + CK6 group (dosed and scheduled as above). Tumor volume
and mouse body weight were measured three times weekly and
normalized for baseline values. After 3 weeks of treatment, mice were
sacrificed, and tumor tissue was fixed in 4% formaldehyde or snap frozen
in liquid nitrogen for histopathologic and molecular characterization.Histologic Assessment
Tumor fragments fixed in formaldehyde were embedded in
paraffin blocks and 4-μm sections were cut for hematoxylin and
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assessing the magnitude of necrosis, myxoid degeneration, or fibrosis
using the following grading scheme: 1—minimal (0-10%), 2—low
(N10% and ≤50%), 3—moderate (N50% and ≤90%), and 4—high
(N90%) grade [19,20]. In addition, we have also added to the grading
system the area with myxoid degeneration, which is characterized by
the replacement of viable tumor tissue by an amorphous matrix with
low cellularity as a pattern of response to TKI treatment observed
[21]. Mitotic figures and apoptotic cells were counted in 10 high
power fields (0.45-mm field diameter) at ×400 magnification on
H&E staining. Cl-PARP, a marker for apoptotic activity, was assessed
by counting positive cells in 10 high power fields. Additionally, the
antibody Ki67 was used as a measure for proliferative activity and was
scored as the average of Ki67-positive tumor cells on five digital
microscopic pictures taken at ×400 magnification. Microscopy was
performed using the Olympus CH-300 microscope; pictures were
taken with digital camera Color View (all Olympus, Tokyo, Japan).
Western Blot Analysis
Snap frozen tumors collected at the end of the experiment were used
for lysate preparation forWestern blot analysis, as previously described
[16]. Three different tumor lysates were run for each treatment group,
which were run in the adjacent lanes as group-by-group comparison.
For gels comparing the effect of CK6 with imatinib or with sunitinib,
we used the same lysates for control (untreated) and CK6-treated
tumors. Chemiluminescence levels were registered with the FUJI-LAS
Mini 3000 System (Fujifilm, Tokyo, Japan).
Statistical Analysis
Wilcoxon matched-pairs test was used for comparison of tumor
volumes between day 0 and the end of the in vivo experiment. Mann-
Whitney U (MWU) test was performed to compare between different
treatment groups. A P value of b .05 was considered as statistically
significant. For the statistical analysis, STATISTICA 12.0 (StatSoft,
Tulsa, Oklahoma) software was used.
Results
Tumor Volume Assessment
Overall, irrespective of KIT mutational status, untreated GIST
xenografts showed a 2.1-fold increase in tumor volume after 3 weeks
of observation (Table 2).
In general, regardless of KIT genotype, imatinib reduced the tumor
volume to 69% of standardized baseline values. As expected from our
experience with these models and their molecular profile, a significant
tumor regression was observed in the KIT exon 11 mutants UZLX-Table 2. Relative Tumor Volume Assessment in GIST Models after 3 Weeks of Treatment
Relative Tumor Volume after 3 Weeks [Mean % (95% CI)]
All Models KITexon 11
UZLX-GIST1 UZLX-GIST3
Control 209 (81-117) 151 (106-196) 282 (172-392)
CK6 198 (81-116) 152 (111-193) 152 (63-240)
Imatinib 69 (53-79)** 21 (12-30)** 25 (18-32)**
Imatinib + CK6 84 (56-83)** 41 (23-59)** 33 (28-39)**
Sunitinib 36 (23-34)** 22 (8-35)** 23 (18-27)**
Sunitinib + CK6 43 (22-32)** 27 (1-53)** 25 (17-32)**
MWU test was performed for statistical assessment; *P b .05, **P b .005 (compared to control); CI,GIST1, UZLX-GIST3, and UZLX-GIST4. Notably, imatinib also
decreased tumor volume in GIST48 as was described by our group
before [18]. Furthermore, imatinib stabilized tumor volume in the
GIST882 model and an increase of tumor volume was observed in
UZLX-GIST2 under treatment. When all xenograft models were
considered, sunitinib treatment caused the most remarkable effect on
tumor volume, causing a reduction in tumor volume to 36%
compared to baseline (Table 2).
CK6 treatment yielded a reduction in tumor growth rate in the
UZLX-GIST3 model (P = .053, MWU test), whereas tumor burden
increased in a rate similar to untreated control tumors in the other
GIST xenograft models. We did not observe enhanced efficacy on
combining CK6 with TKIs in any GIST xenograft model tested.
Moreover, imatinib single-agent treatment yielded a more pro-
nounced tumor volume reduction than imatinib + CK6 in UZLX-
GIST1, UZLX-GIST2, and GIST48 xenografts but not in the
GIST882 model. In addition, sunitinib was significantly more potent
than sunitinib + CK6 in reducing tumor volume in the GIST48 and
GIST882 models (P b .05, MWU test, sunitinib compared to
sunitinib + CK6).
During in vivo experiments, mouse body weight and health status were
continuously monitored. No major side effects were observed in any of
the treatment arms, and the experimental treatments were well tolerated.
Histopathology
Histologic response. We assessed HR by scoring the extent of
necrosis, myxoid degeneration, or fibrosis in H&E staining of the
tumor specimens collected after 3 weeks of treatment (Figure 1)
[19,20]. Importantly, in the GIST882 and GIST48 models, the
interpretation of HR was indecisive due to the observation of necrotic
and myxoid changes of the stroma in more than 50% of untreated
tumors. In the UZLX-GIST2 and UZLX-GIST4 models, we
observed only minimal to low HR in the majority of tumors.
In the remaining models (UZLX-GIST1 and UZLX-GIST3), HR to
imatinib and even more pronounced with sunitinib was characterized by
the induction of myxoid degeneration. Under imatinib, 50% of UZLX-
GIST1 tumors showed grade 3 HR and the remaining tumors showed
even grade 4HR, while in ULZX-GIST3 all tumors showed grade 2HR.
Under sunitinib tumors in the UZLX-GIST1 and UZLX-GIST3
models, all showed at least grade 3 HR.
Overall, CK6 treatment yielded only minimal to low HR (grade 1
or 2) in GIST models, mainly characterized by necrosis, in ~85% of
tumors, which was comparable to untreated control tumors. No
enhanced histologic change in GIST tumor samples was observed on
combining standard TKIs with CK6.KITexon 9 KITexon 13 KITexon 11 + 17
UZLX-GIST4 UZLX-GIST2 GIST882 GIST48
262 (206-217) 244 (198-291) 169 (132-207) 138 (99-177)
290 (210-370) 250 (211-289) 179 (143-215) 155 (118-191)
45 (28-62)** 168 (148-188)** 100 (66-133)** 16 (11-21)**
50 (32-67)** 194 (177-211)* 92 (75-109)** 46 (28-63)**
19 (10-28)** 80 (69-91)** 37 (29-46)** 15 (8-22)**
24 (14-34)** 62 (50-74)** 65 (46-85)** 53 (38-68)**
confidence interval.
Figure 1. HR was assessed in all tested xenograft models and grouped by treatment. HR was graded by assessing the magnitude of
necrosis, myxoid degeneration, and/or fibrosis on H&E staining: grade 1 (0-10%), grade 2 (N10% and≤50%), grade 3 (N50% and≤90%),
and grade 4 (N90%).
Table 3. Histologic Assessment of Mitotic and Apoptotic Activity, Assessed on Tumors Collected after 3 Weeks of Treatment
Xenograft Model
KITexon 11 KITexon 9 KITexon 13 KITexon 11 + 17
UZLX-GIST1 UZLX-GIST3 UZLX-GIST4 UZLX-GIST2 GIST882 GIST48
Mitosis CK6 ↑1.1 ↑1.2 ↑1.1 =1.0 ↑1.1 =1.0
Imatinib ↓↓↓** ↓↓↓** ↓↓↓** ↓1.5** ↓1.7 ↓19.4**
Imatinib + CK6 ↓↓↓** ↓24.9** ↓↓↓** ↑1.1 ↓1.8 ↓6.4**
Sunitinib ↓↓↓** ↓↓↓** ↓↓↓** ↓↓↓** ↓↓↓** ↓50.9**
Sunitinib + CK6 ↓↓↓** ↓↓↓** ↓↓↓** ↓↓↓** ↓7.8** ↓1.7**
Ki67 CK6 ↑1.2 ↑1.2 ↑1.4** =1.0 ↑1.2 ↓1.2
Imatinib ↓50.1** ↓↓↓** ↓↓↓** ↓1.8** ↓2.1* ↓21.0**
Imatinib + CK6 ↓↓↓** ↓34** ↓↓↓** ↓1.1 ↓2.4* ↓3.6**
Sunitinib ↓↓↓** ↓↓↓** ↓↓↓** ↓39.6** ↓38.7** ↓9.4**
Sunitinib + CK6 ↓↓↓** ↓↓↓** ↓↓↓** ↓33** ↓4.1** ↓1.4*
Apoptosis CK6 ↑1.5 ↓1.4 ↑1.4 ↑1.1 ↑1.1 ↑1.4
Imatinib ↑2.4 ↑4.6** ↑2.3** ↓1.5** ↓2.1** ↑2.2**
Imatinib + CK6 ↓7.5** ↑1.2 ↑1.9** ↓1.1 ↓3.5** ↑1.4**
Sunitinib ↑2.3 ↑8** ↑7.7** ↓5.2** ↑1.4* ↑1.7
Sunitinib + CK6 ↓17.4** ↑7.5** ↑4.4** ↓6.3** ↑1.1 ↑2.1**
Cl-PARP CK6 ↑1.4 ↓1.3 ↑1.4 ↑1.1 ↓1.2 ↑1.1
Imatinib ↑1.4 ↑7.2** ↑1.3 ↓1.8** ↓2.1** ↑1.8**
Imatinib + CK6 ↓8.1** =1.0 ↑1.1 ↓1.2* ↓4.6** ↑1.5*
Sunitinib ↑1.8 ↑11.9** ↑6.9** ↓7.4** ↓1.1 ↑1.4
Sunitinib + CK6 ↓9.5** ↑10.8** ↑3.9** ↓8.3** ↓1.6 ↑1.3*
MWU test was performed for statistical assessment; *P b .05, **P b .005 (compared to control).
↓↓↓—more than 100-fold decrease; H&E—H&E staining, Cl-PARP—Cl-PARP immunostaining. Results are presented as fold changes in comparison with control; upward arrows indicate increase, and downward arrows
represent decrease.
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mitotic and apoptotic activity on H&E staining in the GIST
xenografts after 3 weeks of treatment (Table 3).
Imatinib treatment variably reduced the mitotic activity in all
xenograft models, being particularly remarkable in UZLX-GIST1,
UZLX-GIST3, UZLX-GIST4 (KIT exon 11 mutation), and GIST48
(KIT exon 11 and exon 17 mutation) (all P b .005, MWU test). In
the UZLX-GIST2 (KIT exon 9 mutation) and GIST882 (KIT exon
13 mutation) models, mitotic activity was reduced to a lesser extent
(Table 3). Sunitinib profoundly affected mitotic activity in all GIST
xenograft models (P b .005 in all models, MWU test).
Compared to control, mitotic activity was not significantly reduced
by CK6 single treatment in any GIST xenograft model. The
combination of imatinib or sunitinib with CK6 did not reduce
further the mitotic activity of single TKI therapy, even resulting in a
less potent effect compared to single TKI in certain xenograft models
[e.g.,UZLX-GIST2, UZLX-GIST3, GIST48 for imatinib + CK6 (all
P b .05, MWU test, imatinib vs imatinib + CK6) and GIST48 and
GIST882 for sunitinib + CK6 (P ≤ .05, MWU test, sunitinib vs
sunitinib + CK6)].
Under imatinib, the apoptotic activity was significantly increased
compared to control in UZLX-GIST3, UZLX-GIST4, and GIST48
(P b .005, MWU test). Furthermore, sunitinib significantly inducedFigure 2. Western blot analysis for tumors collectedapoptosis in UZLX-GIST3, UZLX-GIST4, and GIST882 (P b .05,
MWU test).
Single agent CK6 did not induce a significant increase in apoptotic
activity in the GIST xenograft models tested. Combination of CK6
and TKI did not lead to a synergistic pro-apoptotic effect over either
TKI treatment. Of note, in UZLX-GIST2 none of the treatments was
able to induce a significant pro-apoptotic effect and a similar absence
of pro-apoptotic activity was observed under imatinib and imatinib +
CK6 in GIST882 xenografts.
In general, observations on H&E were confirmed by Ki67 and Cl-
PARP immunostaining, which were used as confirmatory markers of
proliferative and apoptotic activity (Table 3).
KIT Expression and Activation
Western blot analysis was performed to assess KIT expression and
activation (Figure 2). As expected, imatinib induced a remarkable
inhibition of KIT phosphorylation in UZLX-GIST1, UZLX-GIST3,
and UZLX-GIST4 xenograft models (KIT exon 11 mutations). In the
GIST882 and UZLX-GIST2 models (KIT exon 13 and exon 9
mutations, respectively), no relevant decrease in KIT phosphorylation
was observed under imatinib. In the GIST48 model, in spite of the
presence of a secondary KIT exon 17 mutation, both sunitinib and
imatinib resulted in a decrease in KIT activation. Sunitinib alsoafter 3 weeks of treatment grouped by treatment.
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xenograft models tested (Figure 2).
Under CK6 alone, we did not observe an inhibition of KIT
expression or activation in any of the GIST xenografts except in the
UZLX-GIST1 model (Figure 2). Furthermore, we did not observe
enhanced decrease in KIT activation on TKI therapy combination
with CK6. Interestingly, in the GIST48 model, single TKI treatment
seemed more potent in decreasing KIT phosphorylation compared to
combination therapy (Figure 2).
Of note, especially in the UZLX-GIST1, UZLX-GIST3, and
GIST48 models, equal protein loading was not optimal particularly in
sunitinib and sunitinib + CK6 cohorts. This observation is most likely
related to the extensive myxoid degeneration observed in those
tumors, leaving almost no viable cells.
Discussion
Despite the remarkable clinical success of imatinib treatment in
GIST, the majority of patients develop secondary resistance to this
agent [7–9,12]. To date, imatinib resistant or intolerant patients are
treated with sunitinib and regorafenib as a second- or third-line
treatment. However, the duration of progression-free survival in the
clinic declines progressively with every further line of treatment.
Hence, there is an important need for alternative treatment methods
beyond the traditional small molecule TKI approach in GIST. In the
majority of cases, secondary resistance mutations are situated in the
intracellular TK1 and TK2 domains of the KIT receptor. Therefore,
targeting the EC domain with monoclonal antibodies could be a
valuable treatment approach in GIST.
In the current study, we have evaluated the efficacy of CK6, a fully
human anti-KIT monoclonal antibody binding to the EC region of
the KIT protein, as a single agent and in combination with TKIs used
as standard of care (imatinib and sunitinib) in GIST. CK6 as a single
agent did not efficiently reduce tumor volume in any of the GIST
xenograft models used in this study. We only observed a delay in
tumor growth in UZLX-GIST3 compared to the untreated control
group. CK6 did not induce a significant decrease in mitotic activity,
and apoptotic activity was only slightly increased in UZLX-GIST1,
UZLX-GIST4, and GIST48 (1.4- to 1.5-fold of the untreated
controls), although these increases were not statistically significant. In
UZLX-GIST1, CK6 showed only a minor inhibitory effect on KIT
phosphorylation; this effect was not observed in other GIST xenograft
models. In general, the combination of CK6 with TKIs did not lead
to improved efficacy of either sunitinib or imatinib compared to the
single-agent regimens in our patient-derived mouse xenograft GIST
models. Recently, Edris and colleagues have shown the potential of
the anti-KIT monoclonal antibody SR1 both in vitro and in vivo[13].
In their study, SR1 yielded a significantly decreased GIST tumor cell
growth and cell surface KIT expression as well as increased
macrophage phagocytosis. There might be several reasons for higher
efficacy of SR1 in comparison to CK6. First of all, there may be
different affinity of the antibodies to different mutated form of KIT
receptor. In our study, we have used six different models characterized
by different KIT mutations. Only one model—cell line–derived
GIST882—was used in both studies and, in the experiment with
SR1, produced smaller tumors than in GIST430, yet with strong
in vivo inhibition by the antibody. Additionally, for our experiments,
we used subcutaneous transplantation of tumor fragments, while in
the study testing SR1, tumors were induced through i.p. injection of
transduced cells. The direct and more efficient delivery of SR1through i.p. injection and its penetration to tumors localized i.p. may
explain better efficacy in the study of Edris et al. Additionally, the
microenvironment in the i.p. engrafted tumors could influence the
tumor cells. Finally, since at least partially the response to SR1 was
assigned to the increased macrophage phagocytosis, also the usage of
different strains of immunosuppressed mouse for in vivo experiments
in both our study and that of Edris et al. cannot be excluded as the
reasons for the different levels of efficiency observed in both studies.
There could be several explanations for the lack of efficacy of the
CK6 antibody in our GIST xenograft models. Tabone-Eglinger and
colleagues have shown that KIT mutations in GIST induce
aberrations in the normal maturation and trafficking of the KIT
protein [22]. These alterations can lead to intracellular retention of
the activated RTK in the cell. This observation is also supported by
Xiang et al., who have shown that intracellular KIT signaling could be
sufficient to drive oncogenesis in KIT-dependent malignancies [23].
Therefore, the lack of antagonistic effects on KIT could be related to
conformational changes imposed by activating KIT mutations,
possibly mediated through maturation and trafficking of the protein
that may eventually not reach the cell surface. Second, monoclonal
antibodies as large molecules cannot be delivered to the cytoplasmic
cell compartment. Hence, if the majority of highly active KIT
oncoproteins are located intracellularly, the effect of the antibody on
plasma membrane–associated KIT could be masked by a dominant
intracellular KIT activation. This could explain why we see a lack of
effect under CK6 treatment in the GIST xenografts tested, while CK6
showed KIT antagonist effects in melanoma, small cell lung
carcinoma, and leukemia research models [14]. Therefore, we
would suggest further studies characterizing the binding properties
of anti-KIT monoclonal antibodies to the GIST mutant KIT receptor
along with thorough analysis of KIT receptor localization in GIST
models. In addition, due to intracellular retention of mutated KIT
oncoproteins, methods should be explored to deliver the active agents
to the intracellular compartment without interfering with the target
specificity [22].
Furthermore, in our study, we had some evidence for antagonism
between CK6 and TKIs in GIST models. Although this observation
was not fully consistent throughout our different experiments, it
warrants further exploration to better understand potential biologic
mechanism of action contributing to these combination effects. A first
mechanism that could explain this observation might be that the
monoclonal antibody is not able to bind potently to all KIT mutants,
due to possible conformational changes caused by the KIT mutation.
Due to the heterozygous nature of KIT mutations in our models and
in the majority of GISTs, a portion of wild-type KIT is also present.
Therefore, if the antibody still binds the wild-type KIT receptor and
targets it for proteasomal degradation, this will lead to a prevalence of
only mutant KIT oncoproteins forming homodimers, resulting in a
functional KIT homozygote. The presence of homozygous KIT
mutations has been associated with more malignant behavior and
tumor progression in GIST [24,25]. Finally, binding of the antibody
could induce conformational changes depending on the KIT
genotype, and it has been shown that sensitivity to TKIs is highly
dependent on the conformation of the KIT protein [26–28]. In
addition, the suggested conformational change could also lead to a
facilitation of receptor dimerization, which may result in increased
oncogenic signaling [29].
In conclusion, we were not able to demonstrate significant anti-
tumor effects of CK6, a monoclonal KIT antibody, in our GIST
118 Therapeutic Efficacy Assessment of CK6 Van Looy et al. Translational Oncology Vol. 8, No. 2, 2015xenograft models under the applied experimental conditions.
Moreover, we did not observe synergy of the agent with TKIs, but
some of our findings suggest that such combination in GIST could
lead to decreased anti-tumor efficacy. Our results warrant further
exploration of the properties of monoclonal antibodies in relation to
the different mutational variants of KIT oncoprotein in vitro and
in vivo. Additional preclinical studies testing the combination of small
molecule kinase inhibitors with KIT-specific antibodies should be
designed in a way to specifically detect, through extensive molecular
analysis, any potential antagonism between these two drug classes.
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